A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021–2025)

Expert Opinion on Therapeutic Patents · Published 2026-07-28 · DOI 10.1080/13543776.2026.2704853

Authors (3)

Haixiang Qi, Jiayang Wen, Heng Xu

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Qi, H., Wen, J., Xu, H. (2026). A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021–2025). Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2026.2704853

Related articles